Key result
Novel selenadiazole derivative antagonizes doxorubicin resistance in breast cancer cells via AMPK and ROS-mediated apoptosis.
Why the study?
Hyperglycemia contributes to chemoresistance in breast cancer patients with diabetes, and strategies to overcome this resistance are needed.
Does a synthetic selenadiazole derivative antagonize doxorubicin resistance in MCF-7 breast cancer cells under hyperglycemic conditions?
Does a synthetic selenadiazole derivative antagonize doxorubicin resistance in MCF-7 breast cancer cells under hyperglycemic conditions?
A novel selenadiazole derivative may overcome hyperglycemia-induced doxorubicin resistance in breast cancer cells by activating AMPK-mediated pathways and enhancing ROS-induced apoptosis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for overcoming doxorubicin resistance in diabetic breast cancer; leaves open translation from cell models to clinical use.
Hyperglycemia is an important factor for chemoresistance of breast cancer patients with diabetes. In the present study, a novel selenadiazole derivative has been evaluated and found to be able to antagonize the doxorubicin (DOX) resistance of MCF-7 cells under simulated diabetes conditions. Hyperglycemia promotes the proliferation, invasion and migration of MCF-7 cells through activation of ERK and AKT pathways, which could be inhibited by the synthetic selenadiazole derivative. The antitumor effects of the selenadiazole derivative were attributed to its ability to activate AMPK pathways. Furthermore, the high lipophilicity (log P = 1.9) of the synthetic selenadiazole derivative facilitated its uptake by cancer cells and subsequently potentiated the cellular uptake of DOX, leading to a strong enhancment of the antiproliferative activity of DOX on MCF-7 cells by induction of apoptosis. The apoptosis was initiated by the ROS overproduction induced by the cooperation of the selenadiazole derivative and DOX. The excessive ROS then caused damage to DNA, which upregulated the expression of proapoptosis Bcl-2 family proteins and led to fragmentation of mitochondria, which finally caused apoptosis of the cancer cells. Taken together, this study provides a rational strategy for using selenadiazole derivatives to overcome hyperglycemia-induced drug resistance in breast cancer by activation of AMPK-mediated pathways.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2017) studied Breast cancer with hyperglycemia-induced drug resistance. Selenadiazole derivative was evaluated on Antagonism of doxorubicin resistance and induction of apoptosis. A novel selenadiazole derivative antagonized doxorubicin resistance in MCF-7 breast cancer cells under simulated diabetes conditions by activating AMPK pathways and inducing ROS-mediated apoptosis.
Synapse has enriched 10 related papers. Consider them for comparative context: